Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: A pilot study

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 3, 2012, Pages 450-460

  Mortazavi Jehanno, Nina ^a   Giraudet, Anne Laure ^a   Champion, Laurence ^a   Lerebours, Florence ^a   Le Stanc, Elise ^b   Edeline, Veronique ^a   Madar, Olivier ^a   Bellet, Dominique ^a,c   Pecking, Alain Paul ^a   Alberini, Jean Louis ^a,d  

^a INSTITUT CURIE   (France)

^b FOCH HOSPITAL   (France)

^c FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

^d LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

18F FDG; Endocrine therapy; Metastatic breast cancer; PET CT; Therapy response

Indexed keywords

ANASTROZOLE; EXEMESTANE; FLUORODEOXYGLUCOSE F 18; FULVESTRANT; GOSERELIN; LETROZOLE; LEUPRORELIN; MEGESTROL; MEGESTROL ACETATE; TAMOXIFEN; TRIPTORELIN;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; METABOLISM; PILOT STUDY; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HORMONES; HUMANS; MIDDLE AGED; MUCIN-1; NEOPLASM METASTASIS; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RECURRENCE; TREATMENT OUTCOME;

EID: 84859649230     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1981-z     Document Type: Article

References (40)

1. Beslija S, Bonneterre J, Burstein H, Cocquyt V, Gnant M, Heinemann V, et al.; Central European Cooperative Oncology Group (CECOG). Third consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2009;20:1771-85.
2. Kuukasjärvi T, Kononen J, Helin H, Holli K, Isola J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol. 1996;14:2584-9. (Pubitemid 26300127)
3. Kaufmann M, von Minckwitz G, Bear H, Buzdar A, McGale P, Bonnefoi H, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. 2007;18:1927-34. (Pubitemid 350286227)
4. Schelling M, Avril N, Nahrig J, Kuhn W, Romer W, Sattler D. Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol. 2000;18:1689-95. (Pubitemid 30220547)
5. Smith I, Welch A, Hutcheon A, Miller I, Payne S, Chilcott F. Positron emission tomography using [(18)]-(fluorine-18)-fluorodeoxy- D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol. 2000;18:1676-88. (Pubitemid 30220546)
6. Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L, et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2006;24:5366-72. (Pubitemid 46623167)
7. Berriolo-Riedinger A, Touzery C, Riedinger JM, Toubeau M, Coudert B, Arnould L, et al. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2007;34:1915-24. (Pubitemid 350212117)
8. McDermott G, Welch A, Staff R, Gilbert F, Schweiger L, Semple S, et al. Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat. 2007;102(1):75-84. (Pubitemid 46294965)
9. Schwarz-Dose J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S, et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol. 2009;27:535-41.
10. Duch J, Fuster D, Munoz M, Fernandez PL, Paredes P, Fontanillas M, et al. 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging. 2009;36:1551-7.
11. Dose Schwarz J, Bader M, Jenicke L, Hemminger G, Jänicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med. 2005;46:1144-50. (Pubitemid 43741076)
12. Couturier O, Jerusalem G, N'Guyen J, Hustinx R. Sequential positron emission tomography using [18F]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer. Clin Cancer Res. 2006;12:6437-43. (Pubitemid 44799716)
13. Specht J, Tam S, Kurland B, Gralow J, Livingston R, Linden H, et al. Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Res Treat. 2007;105:87-94. (Pubitemid 47282751)
14. Dehdashti F, Flanagan F, Mortimer J, Katzenellenbogen J, Welch M, Siegel B. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med. 1999;26:51-6. (Pubitemid 29137739)
15. Mortimer J, Dehdashti F, Siegel B, Trinkaus K, Katzenellenbogen J, Welch M. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol. 2001;19:2797-803. (Pubitemid 32538187)
16. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma A, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773-82. (Pubitemid 29512308)
17. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-81.
18. Hamaoka T, Madewell J, Podoloff D, Hortobagyi G, Ueno N. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004;22:2942-53. (Pubitemid 41079914)
19. Du Y, Cullum I, Illidge T, Ell P. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positronemission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol. 2007;25:3440-7. (Pubitemid 47310881)
20. Tateishi U, Gamez C, Dawood S, Yeung H, Cristofanilli M, Macapinlac H. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of systemic therapy with integrated PET/CT. Radiology. 2008;247:189-96.
21. Schneider-Kolsky M, Hart S, Fox J, Midolo P, Stuckey J, Hofman M, et al. The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET. Breast Cancer Res. 2010;12:R37.
22. Ueda S, Tsuda H, Saeki T, Omata J, Osaki A, Shigekawa T, et al. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study. Breast Cancer. 2010;16:660-2.
23. Bos R, van Der Hoeven J, van Der Wall E, van Der Groep P, van Diest P, Comans E, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;15:379-87. (Pubitemid 34072519)
24. Buck A, Schirrmeister H, Kuhn T, Shen C, Kalker T, Kotzerke J, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging. 2002;29:1317-23. (Pubitemid 44392212)
25. Shimoda W, Hayashi M, Murakami K, Oyama T, Sunagawa M. The relationship between FDG uptake in PET scans and biological behavior in breast cancer. Breast Cancer. 2007;14:260-8.
26. Smith I, Dowsett M, Ebbs S, Dixon J, Skene A, Blohmer J, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23:5108-16. (Pubitemid 46224019)
27. Dowsett M, Smith I, Ebbs S, Dixon J, Skene A, Griffith C, et al. Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin Cancer Res. 2006;12:1024s-30s. (Pubitemid 43259839)
28. Dowsett M, Smith I, Ebbs S, Dixon J, Skene A, A'Hern R, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007;99:167-70.
29. Huyge V, Garcia C, Alexiou J, Ameye L, Vanderlinden B, Lemort M, et al. Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients. Clin Oncol (R Coll Radiol). 2010;22:818-27.
30. Champion L, Brain E, Giraudet A, Le Stanc E,Wartski M, Edeline V, et al. Breast cancer recurrence diagnosis suspected on tumor marker rising: value of whole-body 18FDG-PET/CT imaging and impact on patient management. Cancer. 2011;117:1621-9.
31. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287-312. (Pubitemid 350232263)
32. Ellis M, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Jänicke F, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001;19:3808-16. (Pubitemid 32880059)
33. Mintun M, Welch M, Siegel B, Mathias C, Brodack J, McGuire A, et al. Breast cancer: PET imaging of estrogen receptors. Radiology. 1988;169:45-8.
34. McGuire A, Dehdashti F, Siegel B, Lyss A, Brodack J, Mathias C, et al. Positron tomographic assessment of 16a-[18F]fluoro-17b-estradiol uptake in metastatic breast carcinoma. J Nucl Med. 1991;32:1526-31.
35. Linden H, Stekhova S, Link J, Gralow J, Livingston R, Ellis G, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol. 2006;24:2793-9. (Pubitemid 46630578)
36. Dehdashti F, Mortimer J, Trinkaus K, Naughton M, Ellis M, Katzenellenbogen J, et al. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor- positive breast cancer. Breast Cancer Res Treat. 2009;113:509-17.
37. Ko B, Paik J, Jung K, Lee K. 17b-Estradiol augments 18F-FDG uptake and glycolysis of T47D breast cancer cells via membraneinitiated rapid PI3K-Akt activation. J Nucl Med. 2010;51:1740-7.
38. Pio BS, Park CK, Pietras R, Hsueh WA, Satyamurthy N, Pegram MD, et al. Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol. 2006;8:36-42. (Pubitemid 44201576)
39. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′- deoxy-3′-[(18)F] fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging. 2007;34:1339-47. (Pubitemid 47312585)
40. Lindholm P, Lapela M, Någren K, Lehikoinen P, Minn H, JyrkkiöS. Preliminary study of carbon-11 methionine PET in the evaluation of early response to therapy in advanced breast cancer. Nucl Med Commun. 2009;30:30-6.